Placebo News and Research

RSS

Cotellic (cobimetinib) approved to be used in combination with vemurafenib for melanoma treatment

The U.S. Food and Drug Administration today approved Cotellic (cobimetinib) to be used in combination with vemurafenib to treat advanced melanoma that has spread to other parts of the body or can't be removed by surgery, and that has a certain type of abnormal gene (BRAF V600E or V600K mutation).

10 Nov 2015

Drinking one 16-ounce energy drink may increase risk of cardiovascular events in young adults

New research shows that drinking one 16-ounce energy drink can increase blood pressure and stress hormone responses significantly. This raises the concern that these response changes could increase the risk of cardiovascular events, according to a study presented today at the American Heart Association's Scientific Sessions 2015.

10 Nov 2015

Idera begins enrollment in IMO-8400 Phase 2 clinical trial for treatment of dermatomyositis

Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing Toll-like receptor (TLR) and RNA therapeutics for patients with cancer and rare diseases, today announced that the company has commenced enrollment in a Phase 2 clinical trial of IMO-8400, an investigational TLR 7, 8 and 9 antagonist, in patients with dermatomyositis. Dermatomyositis is a rare and debilitating inflammatory muscle and skin disease associated with significant morbidity, decreased quality of life and an increased risk of premature death.

10 Nov 2015

Isosorbide mononitrate does not increase HFpEF patients' daily activity level

Heart failure patients with preserved ejection fraction (HFpEF) -- where the heart becomes stiff and cannot relax or fill properly -- did not have increased exercise tolerance after taking isosorbide mononitrate, compared to a placebo, according to a study presented today at the American Heart Association's Scientific Sessions 2015.

10 Nov 2015

Sorafenib increases progression-free survival and disease control rate in NSCLC patients

Sorafenib, a tyrosine kinase inhibitor (TKI) targeting the receptors for vascular endothelial growth factor, platelet derived growth factor, and mast/stem cell growth factor, modestly increases progression-free survival (PFS), time to progression, and disease control rate in non-small cell lung cancer (NSCLC) patients who have relapsed or failed two or three previous treatment regimens.

10 Nov 2015

Type 2 diabetes drug significantly reduces hospitalizations, death from heart failure

For the first time, research shows that a type 2 diabetes drug significantly reduces hospitalizations and death from heart failure.

10 Nov 2015

New review finds scant scientific evidence supporting use of cannabinoids in rheumatic diseases

Although there are anecdotal reports indicating that cannabinoids, especially marijuana (or herbal cannabis), may be of therapeutic benefit for some patients with rheumatic complaints, a new review published in Arthritis Care & Research, a journal of the American College of Rheumatology, finds scant scientific evidence supporting any use of cannabinoids in rheumatic diseases. Furthermore, not a single controlled study has examined herbal cannabis in the rheumatology patient population.

10 Nov 2015

Armaron Bio starts Phase 2 trial for novel lead candidate drug for heart failure

Armaron Bio, a Melbourne-based drug development company focused on heart failure and other diseases, is pleased to announce that it has begun its Phase II clinical trial for NP202, its novel lead candidate drug for heart failure.

9 Nov 2015

Medication not psychotherapy intensity sways treatment outcome in adult ADHD

Psychological interventions for adult attention deficit/hyperactivity disorder are best combined with methylphenidate, show findings from the COMPAS trial.

9 Nov 2015

Energy drink consumption linked with serious cardiovascular events

Anna Svatikova, M.D., Ph.D., of the Mayo Clinic, Rochester, Minn., and colleagues randomly assigned 25 healthy volunteers (age 18 years or older) to consume a can (480 mL; 16 fl. oz.) of a commercially available energy drink (Rockstar; Rockstar Inc) and placebo drink within 5 minutes, in random order on 2 separate days, maximum 2 weeks apart.

9 Nov 2015

Diabetes drug liraglutide ineffective in patients with advanced heart failure

In an attempt to correct defects in the energy generation that contributes to poor pump function among heart failure patients, researchers examined whether the diabetes drug liraglutide, could improve the condition of patients with advanced heart failure. Despite improvements in blood sugar control, the therapy did not improve the clinical stability or pumping action of the heart in patients with advanced heart failure.

9 Nov 2015

$Ixazomib’s phase 3 study in relapsed/refractory multiple myeloma presented$

Ixazomib’s phase 3 study in relapsed/refractory multiple myeloma presented

Takeda Pharmaceutical Company Limited today announced that it will present Phase 3 data from the TOURMALINE-MM1 ixazomib clinical trial at the 57th American Society of Hematology (ASH) Annual Meeting to be held in Orlando, Florida from December 5 to 8, 2015.

6 Nov 2015

New tool could help identify patients most likely to benefit from chemoprevention

A team of scientists, led by researchers at University of California, San Diego Moores Cancer Center and The University of Texas MD Anderson Cancer Center, report that a genetic biomarker called loss of heterozygosity or LOH is able to predict which patients with premalignant mouth lesions are at highest risk of developing oral cancer.

6 Nov 2015

Vanderbilt wins NIA grant to study effectiveness of nicotine patch in improving memory loss in older adults with MCI

Vanderbilt University Medical Center has received a $9.4 million grant from the National Institute on Aging to test the effectiveness of a transdermal nicotine patch in improving memory loss in older adults with mild cognitive impairment (MCI), a precursor to Alzheimer's disease.

6 Nov 2015

Multicenter trial compares popular treatments for menopause-related vaginal symptoms

Hot flashes. Night sweats. These are the most common - or at least the most commonly talked about - symptoms of menopause. But one reality of The Change for many women is less discussed yet no less important: problems with vaginal health and sexual function.

6 Nov 2015

RXi Pharmaceuticals begins Phase 1/2 clinical trial in ophthalmology

RXi Pharmaceuticals Corporation a biotechnology company focused on discovering and developing innovative therapies primarily in the areas of dermatology and ophthalmology today announced the initiation of a Phase 1/2 clinical trial in ophthalmology. The clinical study RXI-109-1501 will evaluate the safety and clinical activity of RXI-109 to prevent the progression of retinal scarring, a harmful component of numerous retinal diseases.

5 Nov 2015

Expressive writing may improve functioning among combat veterans with reintegration problems

In a study of nearly 1,300 returning veterans reporting reintegration problems, those who completed online expressive-writing sessions showed more improvements than peers who had not written at all or who had engaged only in factual writing.

5 Nov 2015

New research finds insufficient evidence for use of Omega 3 supplements in treating major depressive disorder

New research out today concludes that there is insufficient evidence for the use of taking an Omega 3 fatty acid supplement in treating major depressive disorder.

5 Nov 2015

Estrogen-like drug may not be beneficial to women with Alzheimer's dementia

An estrogen-like drug, raloxifene, has no demonstrated benefit on memory and thinking skills for women with dementia due to Alzheimer's disease, according to a study published in the November 4, 2015, online issue of Neurology, the medical journal of the American Academy of Neurology.

5 Nov 2015

Nucala (mepolizumab) approved for treatment of asthma patients

The U.S. Food and Drug Administration today approved Nucala (mepolizumab) for use with other asthma medicines for the maintenance treatment of asthma in patients age 12 years and older. Nucala is approved for patients who have a history of severe asthma attacks (exacerbations) despite receiving their current asthma medicines.

5 Nov 2015

Placebo News and Research

Cotellic (cobimetinib) approved to be used in combination with vemurafenib for melanoma treatment

Drinking one 16-ounce energy drink may increase risk of cardiovascular events in young adults

Idera begins enrollment in IMO-8400 Phase 2 clinical trial for treatment of dermatomyositis

Isosorbide mononitrate does not increase HFpEF patients' daily activity level

Sorafenib increases progression-free survival and disease control rate in NSCLC patients

Type 2 diabetes drug significantly reduces hospitalizations, death from heart failure

New review finds scant scientific evidence supporting use of cannabinoids in rheumatic diseases

Armaron Bio starts Phase 2 trial for novel lead candidate drug for heart failure

Medication not psychotherapy intensity sways treatment outcome in adult ADHD

Energy drink consumption linked with serious cardiovascular events

Diabetes drug liraglutide ineffective in patients with advanced heart failure

Ixazomib’s phase 3 study in relapsed/refractory multiple myeloma presented

New tool could help identify patients most likely to benefit from chemoprevention

Vanderbilt wins NIA grant to study effectiveness of nicotine patch in improving memory loss in older adults with MCI

Multicenter trial compares popular treatments for menopause-related vaginal symptoms

RXi Pharmaceuticals begins Phase 1/2 clinical trial in ophthalmology

Expressive writing may improve functioning among combat veterans with reintegration problems

New research finds insufficient evidence for use of Omega 3 supplements in treating major depressive disorder

Estrogen-like drug may not be beneficial to women with Alzheimer's dementia

Nucala (mepolizumab) approved for treatment of asthma patients

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Latest News